10-Q: Exicure Inc. Reports Third Quarter 2024 Results Amid Strategic Shift and Financial Uncertainty

Exicure Inc. reported its third quarter 2024 results, highlighting a strategic shift towards exploring new opportunities while facing significant financial challenges and going concern doubts.

Summary

• Exicure Inc., historically a biotechnology company, is now exploring strategic alternatives to maximize stockholder value.
• The company sold its historical biotechnology intellectual property in September 2024 for $1.5 million, recognizing it as other income.
• For the nine months ended September 30, 2024, Exicure reported a net loss of $2.52 million, compared to a net loss of $15.43 million for the same period in 2023.
• The company's cash and cash equivalents stood at $343,000 as of September 30, 2024, down from $816,000 at the end of 2023.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to insufficient cash and the need for substantial additional financing in the near term.
• The company is seeking financing through equity offerings, but there is no guarantee that it will be available or on favorable terms.
• Exicure is also facing challenges in maintaining its Nasdaq listing, including minimum stockholders equity and stock price requirements.

Sentiment

Score: 2

Explanation: The document presents a highly negative outlook due to the company's financial instability, going concern doubts, and Nasdaq listing challenges. While there are some positive developments, such as the sale of assets and potential investments, the overall sentiment is very poor.

Positives

• The company generated $1.5 million in other income from the sale of its historical biotechnology intellectual property.
• The net loss for the nine months ended September 30, 2024, decreased significantly compared to the same period in 2023.
• The company has secured a $1.3 million investment from HiTron Systems Inc. expected to close soon.
• The company has an additional $8.7 million investment pending from HiTron Systems Inc. subject to stockholder approval.

Negatives

• The company's cash and cash equivalents have decreased significantly.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company is not in compliance with Nasdaq's minimum stockholders equity requirement.
• Exicure has received a delisting determination from Nasdaq staff.
• The company has a history of losses and expects to continue to incur significant losses for the foreseeable future.
• The company has material weaknesses in its internal control over financial reporting.

Risks

• The company's exploration of strategic alternatives may not be successful.
• The company needs to obtain substantial funding in the very near term to continue operations.
• There is uncertainty about the timing and amount of any royalties or license payments from the sale of historical assets.
• The company may not be able to redeem its investment in convertible notes receivable.
• The company's controlling stockholders and management have limited experience with U.S. public companies.
• There is a risk of turnover in the board and senior management.
• The company may be delisted from Nasdaq.
• The company's internal computer systems may fail or suffer security breaches.
• The company is subject to ongoing legal proceedings.
• The company's ability to use net operating loss carryforwards may be limited.

Future Outlook

The company's future is uncertain and dependent on its ability to secure additional financing and successfully execute strategic alternatives. The company expects to incur significant expenses and negative cash flows for the foreseeable future. The company's ability to generate revenue from royalties and license fees from the sale of its historical assets is uncertain.

Management Comments

• Management believes that, given the Company's current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.
• Substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified.

Industry Context

The company's shift from a biotechnology focus to exploring strategic alternatives reflects a broader trend of companies seeking new avenues for growth and value creation in a challenging market environment. The company's financial difficulties highlight the risks associated with early-stage biotechnology companies and the need for strong financial planning and execution.

Comparison to Industry Standards

• Exicure's financial performance is significantly below industry standards for biotechnology companies, particularly in terms of revenue generation and cash reserves.
• The company's lack of ongoing revenue and reliance on equity financing is not uncommon for early-stage biotech companies, but the severity of Exicure's financial situation is concerning.
• The company's decision to sell its historical assets and explore strategic alternatives is a common strategy for companies facing financial difficulties, but the success of this approach is not guaranteed.
• Compared to other companies in the biotechnology sector, Exicure's current situation is more precarious due to its limited cash reserves, lack of revenue, and ongoing Nasdaq listing challenges. Companies such as Alnylam Pharmaceuticals and Moderna, while also facing challenges, have significantly more robust financial positions and established revenue streams.
• The company's reliance on a potential investment from HiTron Systems Inc. is a high-risk strategy, as the closing of the investment is subject to various conditions, including stockholder approval. This contrasts with companies that have diversified funding sources and a more stable financial outlook.

Legal Proceedings

• The company is involved in a securities class action lawsuit, which has received preliminary approval for settlement.
• The company is involved in multiple shareholder derivative lawsuits.
• The company is involved in a legal dispute with a former employee.

Related Party Transactions

• The company has a consulting agreement with Alta Companies LTD, where Paul Kang, a director and CEO of the company, is the President.
• The company received a loan of $700,000 from DGP Co., Ltd., a related party, which was later converted to equity.
• The company has agreements to sell shares to HiTron Systems Inc., which will become a related party after the closing of the initial investment.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and potential delisting from Nasdaq.
• Employees face uncertainty due to the company's financial difficulties and potential for further reductions in force.
• Customers and suppliers may be impacted by the company's strategic shift and potential for business disruption.
• Creditors face risks due to the company's financial instability and potential for bankruptcy.

Next Steps

• The company will continue to explore strategic alternatives.
• The company will seek additional financing through equity offerings.
• The company will attempt to regain compliance with Nasdaq listing requirements.
• The company will seek stockholder approval for the $8.7 million investment from HiTron Systems Inc.

Key Dates

Keywords

strategic alternatives, biotechnology, financial results, going concern, Nasdaq listing, capital raise, reverse stock split, intellectual property, HiTron Systems Inc., debt for equity